Using an epigenetic mechanism, romidepsin restored gene expression and alleviated social deficits in animal models of autism
Aseptika in St Ives and Zenzium in Cheshire have been awarded an unspecified grant from the UK’s innovation agency to leverage AI and develop a new home-based early warning system for people with severe respiratory disease.
Erdafitinib, an oral pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, shows promise as the first targeted agent for patients with metastatic urothelial cancer, one of the most common cancers
mHealth tools embedded with AI technology are helping doctors and those living with diabetes detect hyperglycemia and hypoglycemia up to an hour ahead of time, averting serious and potentially fatal health issues.
Investors who pressed GlaxoSmithKline to slash new CEO Emma Walmsley’s pay package before she took the helm probably won’t much like her overall compensation figure for 2017.
Cancer cells are different from normal cells in that they can avoid a naturally programmed cell death process known as apoptosis and grow almost indefinitely. In their third collaboration, Boehringer Ingelheim and Vanderbilt University have their eyes on a target that helps cancer cells evade death.
As brain cells age, they lose their ability to perform basic functions, often leading to dementia and other neurodegenerative disorders. But what’s behind this decline, and can it be stopped? Two new studies out this week uncover links between genes and brain-cell functioning that could provide new targets for therapies aimed at neurodegenerative diseases.
Researchers from Cardiff University have created the world’s first synthetic, non-biologic vaccine.
SBRI Healthcare alumni and Cambridge-based Owlstone Medical has announced that it has raised $15 million (£11 million) to drive the global commercialisation of its Breath Biopsy® platform.
Five months after its lead drug began Phase I testing San Diego-based Crinetics Pharmaceuticals Inc has secured $63.5 million in Series B financing.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.